Skip to main content
. 2021 May 5;21:356–366. doi: 10.1016/j.omto.2021.04.016

Figure 1.

Figure 1

Oncolytic Vaccinia virus (VV) and Semliki Forest virus (SFV) encoding the GD2 mimotope (GD2m)

(A and B) Schematic illustration of VV Western Reserve (VVWR) and SFV constructs used in the study. (C) GD2m expression in NXS2 tumors injected with VV-dTK or VV-GD2m (i.t.), visualized by immunohistochemical staining. Tumors were collected 2 days after virus injection, and the tumor tissue section was stained with anti-c-Myc antibody and DAPI. Scale bars, 50 μm. (D and E) GD2m expression in NXS2 tumors injected with SFV or SFV-GD2m (i.t.). Tumors were harvested 2 days after virus injection and single-cell suspension was prepared and stained with anti-c-Myc antibody. Representative histogram figures were shown. (F) Representative histogram showing binding of the anti-GD2 antibody to cells infected with VV-GD2m. B16-F10 cells were infected with VV-GD2m (MOI 0.1) and were collected after 48 h. Cells were stained with anti-GD2 antibody (clone 14G2a) and secondary goat anti-rabbit-AF647 antibody and analyzed by flow cytometry. NXS2 cells (naturally expressing GD2) were used as a positive control. VV-GD2m-infected B16-F10 cells stained with only secondary goat anti-rabbit-AF647 antibody were used as a negative control.